Stanford V program for locally extensive and advanced Hodgkin lymphoma: The Memorial Sloan-Kettering Cancer Center experience Journal Article


Authors: Edwards-Bennett, S. M.; Jacks, L. M.; Moskowitz, C. H.; Wu, E. J.; Zhang, Z.; Noy, A.; Portlock, C. S.; Straus, D. J.; Zelenetz, A. D.; Yahalom, J.
Article Title: Stanford V program for locally extensive and advanced Hodgkin lymphoma: The Memorial Sloan-Kettering Cancer Center experience
Abstract: Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially 5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS)>= 4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS 4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.
Keywords: chemotherapy; standard; hodgkin lymphoma; trial; disease; combined modality; involved-field radiotherapy; stanford v; abvd; hazards; mopp
Journal Title: Annals of Oncology
Volume: 21
Issue: 3
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2010-03-01
Start Page: 574
End Page: 581
Language: English
ACCESSION: ISI:000276045300022
DOI: 10.1093/annonc/mdp337
PROVIDER: wos
PUBMED: 19759185
Notes: --- - Article - "Source: Wos"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Zhigang Zhang
    427 Zhang
  2. Joachim Yahalom
    625 Yahalom
  3. Carol Portlock
    204 Portlock
  4. Craig Moskowitz
    407 Moskowitz
  5. Ariela Noy
    351 Noy
  6. Andrew D Zelenetz
    767 Zelenetz
  7. David J Straus
    356 Straus
  8. Eijean Wu
    3 Wu
  9. Lindsay Jacks
    37 Jacks